-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14

Benzinga·08/10/2026 14:13:24
Listen to the news
Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $15 to $14.